Peers of Akebia Therapeutics Inc (AKBA)
Side-by-side comparison
Health Care · Biotechnology
Stock price divided by trailing twelve-month (TTM) GAAP earnings per share. Shows how much investors pay for each dollar of recent profit.
Latest P/E Ratio
-7.35x
As of Oct 9, 2026
Beyond P/E Ratio, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | P/E Ratio |
|---|---|
| Oct 9, 2026 | -7.35x |
| Oct 8, 2026 | -7.46x |
| Oct 7, 2026 | -8.00x |
| Oct 6, 2026 | -8.05x |
| Oct 5, 2026 | -8.34x |
| Oct 2, 2026 | -7.92x |
| Oct 1, 2026 | -7.98x |
| Sep 30, 2026 | -8.43x |
P/E Ratio = Current Stock Price ÷ Trailing 12-Month (TTM) Diluted EPS (or Market Cap ÷ TTM Net Income). Chartloom divides stock price by trailing twelve-month EPS, calculated by dividing TTM net income by the weighted-average share count from filings. Note: Variations in share-count conventions across data providers may cause slight differences in reported P/E multiples.
Trailing P/E is based on reported GAAP results and is one of the most widely used valuation metrics.
Read the general P/E Ratio definition, formula, and analyst usage guide.
P/E Ratio guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
Side-by-side comparison